The study found that triple drug therapy with GABA, DPP-4 inhibitors (sitagliptin), and PPI (omeprazole) has an encouraging therapeutic effect in ameliorating β cell function and managing T1D in non-obese diabetic (NOD) mice (71). This evidence concerns the gene DPP4 and type 1 diabetes mellitus.